RegeneRx Biopharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RGRX research report →
Companywww.regenerx.com
RegeneRx Biopharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue.
- CEO
- J. J. Finkelstein
- IPO
- 2003
- Employees
- 2
- HQ
- Rockville, MD, US
Price Chart
Valuation
- Market Cap
- $748
- P/E
- -0.04
- P/S
- 0.01
- P/B
- -0.02
- EV/EBITDA
- -0.82
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -1826.45%
- Net Margin
- -2249.84%
- ROE
- 60.86%
- ROIC
- 1654.75%
Growth & Income
- Revenue
- $76.76K · 0.00%
- Net Income
- $-1,727,000 · -8.07%
- EPS
- $-1.00 · -7094.24%
- Op Income
- $-1,402,000
- FCF YoY
- 5.01%
Performance & Tape
- 52W High
- $0.16
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.02
- Beta
- 4.73
- Avg Volume
- 223
Get TickerSpark's AI analysis on RGRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 3, 23 | Essetifin SPA | other | 3,750,000 |
| Jul 3, 23 | Essetifin SPA | buy | 0 |
| May 17, 22 | GOLDSTEIN ALLAN L | other | 480,000 |
| May 17, 22 | GOLDSTEIN ALLAN L | other | 480,000 |
| May 17, 22 | Bove Mauro | other | 240,000 |
| May 17, 22 | Bove Mauro | other | 240,000 |
| May 17, 22 | Noseda Alessandro | other | 240,000 |
| May 17, 22 | Noseda Alessandro | other | 240,000 |
| May 17, 22 | Elsey R Don | other | 290,000 |
| May 17, 22 | MCNAY JOSEPH C | other | 290,000 |
Our RGRX Coverage
We haven't published any research on RGRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RGRX Report →